Drug Profile
DPC 368
Latest Information Update: 15 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antidepressants; Anxiolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 01 Jun 2004 No development reported - Phase-I for Anxiety disorders in USA (unspecified route)
- 01 Jun 2004 No development reported - Phase-I for Depression in USA (unspecified route)
- 21 Jun 2001 Phase-I clinical trials for Anxiety disorders in USA (Unknown route)